Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 20/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13093701 | 1.00 | REN (0.77) | REN | |
| SCHEMBL842335 | 1.00 | REN (0.77) | REN | |
| SCHEMBL6854918 | 1.00 | REN (0.77) | REN | |
| SCHEMBL14641792 | 0.95 | REN (0.69) | REN | |
| SCHEMBL12920947 | 0.94 | REN (0.81) | REN | |
| SCHEMBL14476810 | 0.92 | REN (0.76) | REN | |
| SCHEMBL4542652 | 0.92 | REN (0.81) | REN | |
| SCHEMBL4542653 | 0.92 | REN (0.81) | REN | |
| SCHEMBL16371079 | 0.92 | REN (0.81) | REN | |
| SCHEMBL8280530 | 0.91 | REN (0.84) | REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2736875-B1 | CHEMICAL PROCESS FOR OPENING RING COMPOUNDS | CHEMO IBÉRICA S A (ES) | 2015-07-22 | — | — | EP | disclosed |
| US-9067868-B2 | Chemical process for opening ring compounds | CHEMO IBERICA, S.A. (ES) | 2015-06-30 | — | — | US | disclosed |
| US-20140213821-A1 | CHEMICAL PROCESS FOR OPENING RING COMPOUNDS | CHEMO IBERICA, S. A. (ES) | 2014-07-31 | — | — | US | disclosed |
| US-8779198-B2 | Ring opening of lactones and lactams | NOVARTIS AG (CH) | 2014-07-15 | — | — | US | disclosed |
| US-8664440-B2 | Method for preparing aliskiren and its intermediates thereof | ZHEJIANG TIANYU PHARMACEUTICAL CO., LTD (CN) | 2014-03-04 | — | — | US | disclosed |
| US-20130225841-A1 | METHOD FOR PREPARING ALISKIREN AND ITS INTERMEDIATES THEREOF | ZHEJIANG TIANYU PHARMACEUTICAL CO., LTD. (CN) | 2013-08-29 | — | — | US | disclosed |
| US-8143416-B2 | Alternative synthesis of renin inhibitors and intermediates thereof | NOVARTIS AG (CH) | 2012-03-27 | — | — | US | disclosed |
| US-8143416-B2 | Alternative synthesis of renin inhibitors and intermediates thereof | NOVARTIS AG (CH) | 2012-03-27 | — | — | US | disclosed |
| US-20110230665-A1 | SYNTHESIS OF RENIN INHIBITORS INVOLVING A CYCLOADDITION REACTION | MICKEL STUART JOHN | 2011-09-22 | — | — | US | disclosed |
| US-20110230665-A1 | SYNTHESIS OF RENIN INHIBITORS INVOLVING A CYCLOADDITION REACTION | MICKEL STUART JOHN | 2011-09-22 | — | — | US | disclosed |
| EP-1789377-A1 | ALTERNATIVE SYNTHESIS OF RENIN INHIBITORS AND INTERMEDIATES THEREOF | Novartis AG (CH) | 2007-05-30 | — | — | EP | disclosed |
| WO-2007039183-A1 | SYTHESIS OF RENIN INHIBITORS INVOLVING A CYCLOADDITION REACTION | NOVARTIS AG (CH) | 2007-04-12 | — | — | WO | disclosed |
| US-20060154926-A1 | Methods of treating alzheimer's disease using aryl alkanoic acid amides | ELAN PHARMACEUTICALS, INC. | 2006-07-13 | — | — | US | disclosed |
| WO-2006024501-A1 | ALTERNATIVE SYNTHESIS OF RENIN INHIBITORS AND INTERMEDIATES THEREOF | NOVARTIS AG (CH) | 2006-03-09 | — | — | WO | disclosed |
| WO-2006024501-A1 | ALTERNATIVE SYNTHESIS OF RENIN INHIBITORS AND INTERMEDIATES THEREOF | NOVARTIS AG (CH) | 2006-03-09 | — | — | WO | disclosed |
| US-5705658-A | HYPOTENSIVE AGENTS | NOVARTIS CORPORATION (US) | 1998-01-06 | — | — | US | disclosed |
| US-5654445-A | INTERMEDIATES FOR RENIN INHIBITORS, HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1997-08-05 | — | — | US | disclosed |
| US-5646143-A | FOR TREATING A VARIETY OF CONDITIONS | CIBA-GEIGY CORPORATION (US) | 1997-07-08 | — | — | US | disclosed |
| US-5627182-A | RENIN INHIBITORS FOR USE AS HYPOTENSIVE AGENTS | CIBA GEIGY CORPORATION (US) | 1997-05-06 | — | — | US | disclosed |
| US-5559111-A | HYPOTENSIVE AGENTS; RENIN INHIBITORS; Aliskiren | CIBA-GEIGY CORPORATION (US) | 1996-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225841-A1 | METHOD FOR PREPARING ALISKIREN AND ITS INTERMEDIATES THEREOF | FLI1, MLX, LMTK2 | REN 166/4885 |
| US-20060154926-A1 | Methods of treating alzheimer's disease using aryl alkanoic acid amides | BACE1, APP, PSEN1 | REN 970/4885 |
| US-20140213821-A1 | CHEMICAL PROCESS FOR OPENING RING COMPOUNDS | LSS, CILK1, DCXR | REN 2429/4885 |
| US-20110230665-A1 | SYNTHESIS OF RENIN INHIBITORS INVOLVING A CYCLOADDITION REACTION | REN, AGTR1, AGTR2 | REN 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.